Compare ITT & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITT | ALNY |
|---|---|---|
| Founded | 1920 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 21.6B |
| IPO Year | 1994 | 2004 |
| Metric | ITT | ALNY |
|---|---|---|
| Price | $201.23 | $145.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 30 |
| Target Price | $254.92 | ★ $284.96 |
| AVG Volume (30 Days) | 842.2K | ★ 3.1M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | N/A | ★ 206.88 |
| EPS | 3.21 | ★ 18.42 |
| Revenue | ★ $3,938,500,000.00 | $1,037,418,000.00 |
| Revenue This Year | $41.62 | $46.31 |
| Revenue Next Year | $9.56 | $17.44 |
| P/E Ratio | $64.26 | ★ $8.02 |
| Revenue Growth | 8.48 | ★ 22.88 |
| 52 Week Low | $166.96 | $146.51 |
| 52 Week High | $230.32 | $479.79 |
| Indicator | ITT | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 26.11 |
| Support Level | $185.86 | N/A |
| Resistance Level | $218.63 | $168.35 |
| Average True Range (ATR) | 8.02 | 7.80 |
| MACD | -0.42 | 0.38 |
| Stochastic Oscillator | 26.29 | 3.80 |
ITT began its journey as International Telephone & Telegraph in 1920. Through decades of acquisitions in the mid-1900s, ITT went from manufacturing telephone switching equipment to operating hotels, car rentals, insurance agencies, and bread bakeries. In 1995, the firm split into three separate entities, one of which is the ITT in current operation. After a few more spinoffs in 2011, today ITT sells automotive, industrial, and aerospace products such as brake pads, seals, pumps, valves, connectors, and regulators. It has operations around the globe with notable exposure to North America, Europe, and Asia.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.